{"id":"W2511420668","doi":"10.1016/j.atherosclerosis.2016.08.043","title":"A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","year":2016,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"Regeneron Pharmaceuticals; Sanofi","keywords":"Alirocumab; Statin; Medicine; Randomized controlled trial; Internal medicine; Pharmacology; Cholesterol; Total cholesterol","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003428536,0.0004625959,0.001704972,0.000171219,0.0002451046,0.00006646732,0.0002286243,0.0002186015,0.001894867],"category_scores_gemma":[0.002093805,0.0002602736,0.0008691745,0.0003833036,0.00009716282,0.0001561293,0.00005586485,0.0002299416,0.0004040005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000294814,"about_ca_system_score_gemma":0.0004820345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001355877,"about_ca_topic_score_gemma":0.00005599314,"domain_scores_codex":[0.9954025,0.0007753343,0.0009625334,0.0008124114,0.001334841,0.0007123617],"domain_scores_gemma":[0.9966577,0.001099379,0.0003057704,0.001189303,0.0002180226,0.0005298203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7422709,0.0008169106,0.00001506762,0.00003777866,0.0006109329,0.000005558016,0.0007641462,0.000002087904,0.03711863,0.000059095,0.001602794,0.2166961],"study_design_scores_gemma":[0.9687053,0.01152195,0.0001649216,0.0007984256,0.0004246273,0.000009810546,0.0001117036,0.00008663547,0.009465965,0.00009178552,0.008223168,0.0003956901],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857696,0.0002200137,0.00302957,0.002594605,0.0005310397,0.006798803,0.0000448581,0.0002047604,0.0008068065],"genre_scores_gemma":[0.9795393,0.0006489522,0.002205756,0.007200485,0.001917339,0.002319377,0.00001770368,0.0001774292,0.00597371],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2264344,"threshold_uncertainty_score":0.9999849,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06538851783828546,"score_gpt":0.3811616000314036,"score_spread":0.3157730821931182,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}